308 related articles for article (PubMed ID: 37185838)
1. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
4. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
[TBL] [Abstract][Full Text] [Related]
5. Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
Zhou Y; Liu Y; Jiang L; Zhang R; Zhang H; Shi Q; Yang Z; Mao Y; Liu S; Yang Z; Ding J; Zhou Y; Ren B; He L; Zhao X; Li W; Li S; Liu D
J Med Virol; 2023 Dec; 95(12):e29318. PubMed ID: 38112106
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
[No Abstract] [Full Text] [Related]
7. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
[TBL] [Abstract][Full Text] [Related]
8. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
[TBL] [Abstract][Full Text] [Related]
10. Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.
Han X; Li C; Yuan X; Cui J; Han Z; Meng J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Chen W; Xiong J; Zhao D; Zhang X; Han X; Cheng H; Yu Z; Shi Y; Xie W; Xie L
Ann Med; 2024 Dec; 56(1):2313062. PubMed ID: 38354691
[TBL] [Abstract][Full Text] [Related]
11. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
14. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
Jang YR; Oh Y; Kim JY
J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19.
Zeng G; Wang L; Li J; Zhang Z
J Med Virol; 2023 Jun; 95(6):e28836. PubMed ID: 37247396
[No Abstract] [Full Text] [Related]
17. Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19.
Zhang H; Xiaojiao T; Chen J; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38599779
[TBL] [Abstract][Full Text] [Related]
18. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.
Sun Y; Jin L; Dian Y; Shen M; Zeng F; Chen X; Deng G
EClinicalMedicine; 2023 May; 59():101981. PubMed ID: 37193346
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients.
Kim MK; Lee KS; Ham SY; Choi YY; Lee E; Lee S; Lee B; Jeon J; Chin B; Kim Y; Kim G; Jang HC; Choi JP; Park SW
J Korean Med Sci; 2023 Sep; 38(35):e272. PubMed ID: 37667578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
